Shengtai Pharmaceutical to Present at Upcoming Investors Conferences
September 10 2008 - 4:00PM
PR Newswire (US)
- Rodman and Renshaw Annual Global Investment Conference in New
York City - Roth Capital's China Comes to Vegas Conference in Las
Vegas WEIFANG, Shandong, China, Sept. 10
/Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc.
(OTC:SGTI) (BULLETIN BOARD: SGTI) ("Shengtai Pharmaceutical" or
"the Company"), a leading manufacturer and distributor of
high-quality, pharmaceutical grade glucose products in China, today
announced that it has been invited to make corporate presentations
at these upcoming events. The Company announced today that it has
accepted an invitation to present at the Rodman and Renshaw Annual
Global Investment Conference. This conference will be held from
Monday, November 10th through Wednesday, November 12th at the New
York Palace Hotel. The Company will also make a presentation at the
Roth Capital Partners' China Comes to Vegas Conference to be held
from Wednesday, November 19th through Friday, November 21st in Las
Vegas at the Wynn Hotel. Additional details regarding the two
conferences schedule will be available at a later time. "We are
pleased that our investment merit is being recognized and we have
the opportunity to present at these investor conferences," said Mr.
Qingtai Liu, Chief Executive Officer of Shengtai Pharmaceutical.
"The healthcare industry in China continues to outperform the
growth demonstrated by many of today's global economic indicators.
Shengtai is an exciting growth story and we look forward to meeting
with institutional investors to share our vision and corporate
strategy." About Shengtai Pharmaceutical, Inc. Shengtai
Pharmaceutical, Inc. through its wholly-owned subsidiary Shengtai
Holding, Inc. (SHI), a New Jersey corporation, and the Chinese
operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is
a leading manufacturer and supplier of pharmaceutical grade glucose
used for medical purposes, and the glucose and cornstarch products
for the food and beverage industry and for industrial production in
China. For more information about Shengtai Pharmaceutical, Inc.,
please visit http://www.shengtaipharmaceutical.com/ . Safe Harbor
Statement Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: Certain statements in this press
release and oral statements made by the Company constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. These statements include, without limitation, statements
regarding our ability to prepare the company for growth, the
Company's planned capacity expansion in 2008 and predictions and
guidance relating to the Company's future financial performance. We
have based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs but they
involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements,
which may include, but are not limited to, such factors as
unanticipated changes in product demand especially in the
pharmaceutical industry, pricing and demand trends for the
Company's products, changes to government regulations, risk
associated with operation of the Company's new facilities, risk
associated with large scale implementation of the company's
business plan, the ability to attract new customers, ability to
increase its product's applications, cost of raw materials,
downturns in the Chinese economy, and other information detailed
from time to time in the Company's filings and future filings with
the United States Securities and Exchange Commission. Investors are
urged to consider these factors carefully in evaluating the
forward-looking statements herein and are cautioned not to place
undue reliance on such forward-looking statements, which are
qualified in their entirety by this cautionary statement. The
forward-looking statements made herein speak only as of the date of
this press release and the Company undertakes no duty to update any
forward-looking statement to conform the statement to actual
results or changes in the company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms.
Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email:
Grayling Global Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Company Contact, Ms. Melody Shi, CFO, Shengtai
Pharmaceutical, Inc., +1-949-468-7078, or ; Eddie Cheung, Investor
Relations, Grayling Global at +1-646-284-9414 or for Shengtai
Pharmaceutical Web site: http://www.shengtaipharmaceutical.com/
Copyright